Share-based Payment Arrangement, Expense in USD of Kalaris Therapeutics, Inc. from Q2 2019 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Kalaris Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q2 2019 to Q3 2025.
  • Kalaris Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $638K, a 144% increase year-over-year.
  • Kalaris Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $27.3M, a 158% increase year-over-year.
  • Kalaris Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $26.3M, a 35.4% decline from 2023.
  • Kalaris Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $40.8M, a 1.3% decline from 2022.
  • Kalaris Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $41.3M, a 6.05% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

Kalaris Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $27.3M $638K +$376K +144% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-12
Q2 2025 $27M $591K +$269K +83.5% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-13
Q1 2025 $26.7M $374K +$343K +1106% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-14
Q4 2024 $26.3M $25.7M +$15.7M +157% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-07
Q3 2024 $10.6M $262K -$10.2M -97.5% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-12
Q2 2024 $20.8M $322K -$9.97M -96.9% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-13
Q1 2024 $30.8M $31K -$10M -99.7% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-14
Q4 2023 $40.8M $9.99M +$952K +10.5% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-07
Q3 2023 $39.8M $10.5M -$387K -3.57% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $40.2M $10.3M -$663K -6.05% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-09
Q1 2023 $40.9M $10M -$438K -4.19% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 $41.3M $9.04M -$6.82M -43% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-15
Q3 2022 $48.1M $10.9M +$569K +5.53% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-02
Q2 2022 $47.6M $11M +$1.23M +12.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $46.3M $10.5M +$2.36M +29.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $44M $15.9M +$11.4M +258% Oct 1, 2021 Dec 31, 2021 10-K 2023-02-15
Q3 2021 $32.5M $10.3M +$6.43M +166% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $26.1M $9.73M +$9.23M +1877% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $16.9M $8.1M +$7.46M +1154% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 $9.43M $4.43M Oct 1, 2020 Dec 31, 2020 10-K 2022-02-10
Q3 2020 $3.86M +$3.26M +548% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-05
Q2 2020 $492K -$949K -65.9% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 $646K Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q3 2019 $596K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 $1.44M Apr 1, 2019 Jun 30, 2019 10-Q 2020-09-02

Kalaris Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $26.3M -$14.4M -35.4% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-07
2023 $40.8M -$536K -1.3% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-07
2022 $41.3M -$2.66M -6.05% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-15
2021 $44M +$34.5M +366% Jan 1, 2021 Dec 31, 2021 10-K 2023-02-15
2020 $9.43M +$6.54M +226% Jan 1, 2020 Dec 31, 2020 10-K 2022-02-10
2019 $2.89M Jan 1, 2019 Dec 31, 2019 10-K 2021-02-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.